Twice-Daily Deferiprone Well Tolerated in Real-World Anemia Clinical Practice

Twice-daily (BID) deferiprone (DFP) appeared well-tolerated in a real-world study that included patients with thalassemia, sickle cell disease (SCD), or other anemias and transfusional iron overload. Findings from the study were reported in the journal Blood Advances.

The study was conducted to evaluate the safety of DFP BID in this patient population in real-world clinical practice in the US. For analyses, the researchers obtained data from the Ferriprox® Total Care Registry between July 1, 2020, and August 31, 2023, for patients with a referral for DFP BID.